Prostate cancer is often curable. Biochemical disease-free survival and overall survival depend on the initial stage of disease at the time of diagnosis.
Five-year relative survival rates by prostate cancer stage at diagnosis (2014 to 2020 data):[1]National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). Cancer stat facts: prostate cancer [internet publication].
https://seer.cancer.gov/statfacts/html/prost.html
100% (localised disease)
100% (regional)
36.6% (distant)
Ten-year relative survival rates by prostate cancer stage at diagnosis (2011 data):[1]National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). Cancer stat facts: prostate cancer [internet publication].
https://seer.cancer.gov/statfacts/html/prost.html
100% (localised disease)
99.3% (regional)
16.4% (distant)
Genetic factors may have an impact on prognosis. Germline BRCA mutations are associated with a high risk of early-onset prostate cancer, more aggressive disease, and poor survival outcomes.[35]Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013 May 10;31(14):1748-57.
https://ascopubs.org/doi/10.1200/JCO.2012.43.1882?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
http://www.ncbi.nlm.nih.gov/pubmed/23569316?tool=bestpractice.com
[36]Page EC, Bancroft EK, Brook MN, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol. 2019 Dec;76(6):831-42.
https://www.sciencedirect.com/science/article/pii/S0302283819306682?via%3Dihub
http://www.ncbi.nlm.nih.gov/pubmed/31537406?tool=bestpractice.com
One retrospective study found that CDK12-mutated prostate cancers were characterised by aggressive disease features, poor survival outcomes, and poor response to hormonal therapy, PARP inhibitors, and taxanes.[392]Antonarakis ES, Isaacsson Velho P, Fu W, et al. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis Oncol. 2020;4:370-81.
https://ascopubs.org/doi/10.1200/po.19.00399?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
http://www.ncbi.nlm.nih.gov/pubmed/32462107?tool=bestpractice.com
Morbidity
Morbidity resulting from treatment of prostate cancer can be high. Further improvement in radiotherapy planning and delivery will decrease adverse effects and complications (e.g., dysuria, urinary frequency, erectile dysfunction, rectal bleeding, incontinence) and permit administration of higher doses.[393]Budäus L, Bolla M, Bossi A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012 Jan;61(1):112-27.
http://www.ncbi.nlm.nih.gov/pubmed/22001105?tool=bestpractice.com
Mortality and Gleason score at diagnosis
A retrospective cohort study reported on 767 men (ages 55-74 years) diagnosed with localised prostate cancer between 1971 and 1984 who were treated with observation, or with immediate or delayed hormonal therapy.[394]Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):975-80.
http://www.ncbi.nlm.nih.gov/pubmed/9749479?tool=bestpractice.com
[395]Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005 May 4;293(17):2095-101.
https://jamanetwork.com/journals/jama/fullarticle/200821
http://www.ncbi.nlm.nih.gov/pubmed/15870412?tool=bestpractice.com
Men with low-grade prostate cancers (Gleason score 2-4) were at low risk of dying from prostate cancer during 20 years of follow-up (6 deaths per 1000 person-years [95% CI 2 to 11]). Men with high-grade prostate cancers (Gleason score 8-10) were at relatively increased risk of dying from prostate cancer within 10 years of diagnosis (121 deaths per 1000 person-years [95% CI 90 to 156]).[395]Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005 May 4;293(17):2095-101.
https://jamanetwork.com/journals/jama/fullarticle/200821
http://www.ncbi.nlm.nih.gov/pubmed/15870412?tool=bestpractice.com
Few men with low-grade tumours at diagnosis progressed to prostate cancer death; conversely, men with Gleason score 8-10 disease at diagnosis faced a high risk of death from prostate cancer when treated conservatively.[394]Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):975-80.
http://www.ncbi.nlm.nih.gov/pubmed/9749479?tool=bestpractice.com
[395]Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005 May 4;293(17):2095-101.
https://jamanetwork.com/journals/jama/fullarticle/200821
http://www.ncbi.nlm.nih.gov/pubmed/15870412?tool=bestpractice.com
Increasing Gleason score predicted survival difference.